Jump to:
Ray advises both public and private companies in the life sciences industry on strategic transactions, SEC compliance and corporate governance, with a particular focus on venture capital financings, IPOs, PIPEs and other equity capital market transactions. Ray also regularly represents leading life sciences investors, such as Bain Capital Life Sciences, in connection with venture capital, growth equity and public company investment transactions.
Experience
- Represents Bain Capital Life Sciences in their public company investing, including PIPE investments in Dicerna Pharmaceuticals, X4 Pharmaceuticals and Syros Pharmaceuticals.
- Represents leading life sciences investors, including Bain Capital Life Sciences, Redmile, Perceptive Advisers and Newpath in venture capital and growth equity investments
- Represented Tisento Therapeutics in its formation and Series A financing
- Represented Novalis LifeSciences in its PIPE investment in Telesis Bio
- Represented Sarepta Therapeutics in equity financing transactions and SEC reporting
- Represented Provention Bio in equity financing transactions and SEC reporting
- Represented the lead underwriters in IPOs of Elanco Animal Health, CRISPR Therapeutics, Unum Therapeutics and AveXis
- Represented the lead underwriters in the $1.7 billion initial public offering of Elanco Animal Health Incorporated and the dealer managers in the $8.6 billion exchange of Elanco stock for Lilly stock
- Represented PQ Group Holdings Inc., a portfolio company of CCMP, in its $500 million initial public offering
- Represented the lead underwriters in the $56 million initial public offering of CRISPR Therapeutics AG and subsequent $114 million and $200 million follow-on equity offerings
- Represented the lead underwriters in the $69 million initial public offering of Unum Therapeutics Inc.
- Represented the lead underwriters in the $95 million initial public offering of AveXis, Inc.
- Represented Bain Capital Life Sciences in its convertible preferred stock PIPE investment in Dicerna Pharmaceuticals, Inc.
- Represented Bright Horizons Family Solutions, and its private equity sponsor Bain Capital, in multiple secondary offerings
- Represented Sarepta Therapeutics, Inc. in its $375 million follow-on equity offering
- Represented Medtronic plc in connection with its $1.3 billion acquisition of HeartWare International
- Represented IMS Health Holdings, Inc. in multiple 144A debt financings
- Represented the lead underwriters in follow-on equity offerings of bluebird bio, Inc. and Sage Therapeutics, Inc.